Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid ...

The NBDL represents a transition from observing nature as something external to something that is molecularly intimate.

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

DNA nanostructures are exciting new biomedical tools with myriad potential in treatment, diagnosis and disease prevention.

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Tuberculosis (TB) is one of the oldest and deadliest infectious diseases we know. It commonly impacts the lungs, but can also affect other areas of the body like the spine, brain or kidneys.

North America currently leads the DNA Synthesis Market due to its mature biotech ecosystem, heavy investment in genomics, and ...

A new portable DNA test can identify dozens of shark and ray species in only two hours, giving frontline officers a powerful ...

A team from the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER) has developed an innovative ...